Community pharmacies (private retail drug shops/pharmacies) have been used as a differentiated service delivery model for antiretroviral therapy (ART) and are a potential platform to support integrated TB treatment refills for people with TB/HIV. This study used a Human-Centered Design (HCD) methodology to develop an implementation strategy tailored to integrating TB medication refills into community pharmacies in Kampala, Uganda.
The work implemented the inspiration and ideation phases of an HCD process. During the inspiration phase, investigators identified themes capturing barriers and facilitators to integrating TB treatment into community pharmacies and performed observations at community pharmacies to map the care pathway for people with TB/HIV. Qualitative findings were translated into insight statements, design opportunities, and How Might We (HMW) questions to frame solution development.
During the ideation phase, the team conducted brainstorming and co-design workshops that included stakeholders such as people with TB/HIV, TB focal persons, HIV focal persons, Ministry of Health differentiated service delivery (DSD) model experts, and pharmacy healthcare providers. The ideation process generated 26 low-fidelity prototypes. These prototypes were refined through ranked scoring of solutions, and high-fidelity prototypes were assessed for usability using the System Usability Scale. The study focused on co-design and iterative refinement rather than outcome evaluation at this stage.
From the 26 low-fidelity prototypes and subsequent refinement, four implementation strategy components emerged as central to integrating TB treatment into community pharmacies for people with TB/HIV in Kampala:
One core element emphasized raising awareness and building trust in pharmacy-based TB medication refills. Proposed activities focus on engaging TB and HIV focal persons to communicate the privacy, convenience, and legitimacy of pharmacy refill services. Trust-building measures were identified as necessary to encourage people with TB/HIV to use pharmacies for medication refills.
A second component centers on standardizing workflows to support integrated care. This includes synchronizing ART and TB refill schedules, developing standard operating procedures (SOPs), and producing visual diagrams that illustrate how TB treatment can be integrated into existing pharmacy workflows. Standardization aims to streamline processes for patients and pharmacy staff and reduce fragmentation between TB and HIV services.
The third component addresses capacity building for community pharmacies. Proposed measures include certification and accreditation processes and targeted TB training for pharmacy healthcare providers. Strengthening capacity is intended to ensure pharmacies have the knowledge, credentials, and systems to safely handle TB medication refills and engage appropriately with people with TB/HIV.
The final component focuses on monitoring and quality assurance. Recommended tools include SOP manuals and standardized side-effect monitoring checklists to support consistent clinical oversight and documentation. These measures are intended to facilitate quality assurance and ongoing monitoring of pharmacy-based TB refill services.
The adapted implementation strategy and high-fidelity prototypes developed through the HCD process are planned to be evaluated in a pilot randomized trial. That trial will assess both the effectiveness and implementation of integrating TB treatment into community pharmacies for people with TB/HIV in Kampala, Uganda. Details of the pilot trial design, timelines, or outcome measures were not reported in this source.
Ethical approval for the study was provided by the Makerere University Infectious Diseases Institute Research Ethics Committee (reference: IDI-REC-2024-98) and the Uganda National Council for Science and Technology (reference: S4397ES). Administrative clearance was granted by the Directorate of Public and Environmental Health, Kampala Capital City Authority (reference: DPHE/KCCA/1301/01). All participants provided informed consent, either in writing or by thumbprint. The authors declared no competing interests.
Note: The source describes the HCD-derived development process, prototype generation, and intended pilot evaluation. Specific pilot trial details, quantitative usability scores, or evaluation outcomes were not reported in the provided source.